Newsletter 02/2014


Centogene - LifeLabs Canadian partnership :: Centogene's scientific research update

Centogene - LifeLabs Canadian partnership

Centogene's Canadian business was transferred to LifeLabs Medical Laboratory Services ("LifeLabs"), the largest laboratory throughout Canada. Centogene will establish a state-of-the-art genetic laboratory in Ontario, enabling LifeLabs to become the leader with a genetics diagnostic center of excellence in Canada. Genetic and genomic testing are the fastest growing segments in laboratory medicine and form the underlying basis for 'personalized medicine'.

“This partnership brings together LifeLabs’ Canadian presence, reputation and extensive network of sample collection centres throughout Canada with Centogene’s worldwide experience in genetic diagnostics and result interpretation, supported by our unique mutation database,” said Michael Schlenk, CEO of Centogene. “Working together, we will be able to serve patients and providers in the best possible way - especially since both our companies share the same commitment to patient care, quality and innovation.”

For more details, click here

Centogene insights

Pancreatic cancer - better care by revealing genetic causes

Identifying risks before disease onset - researchers from Greifswald and Rostock are working on the first genetic test to detect pancreatitis and pancreatic cancer.

Difficult diagnostics, ambiguous causes  - pancreatitis and pancreatic cancer are typically detected too late.
Developing a reliable genetic test based on a simple blood sample, one that can be used in preventive examinations for those patients at risk for pancreatitis and pancreas carcinoma, is the goal of this ambitious research project, funded by an EU grant.

Smoking and alcohol abuse are the two highest risk factors for pancreatitis, although it is often the case that perfectly healthy people with healthy lifestyles are also afflicted, making it likely that there are genetic factors which also play a role in triggering the disease.

For more details, click here.

CADASIL analysis in co-operation with the Institute for Stroke and Dementia Research

We are pleased to announce the co-operation with the Institute for Stroke and Dementia Research (ISD) at the Ludwig-Maximilian-University in Munich for CADASIL analysis.
The ISD is designed as a novel type of research institute bridging the traditional barriers between academic medicine and basic science. By bringing together a critical mass of excellent scientists and clinicians the ISD facilitates the transfer of basic research findings into clinical applications (bench to bedside) while focussing basic research on clinically relevant questions (bedside to bench).
Centogene is offering for clinical and scientific partners of the ISD a high-end technological genetic service based on its international and national accreditation lines (CAP, CLIA, ISO).

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is the most common inherited cause of stroke and vascular dementia in adults. The clinical presentation of CADASIL varies among and within families. The disease is characterized by five main symptoms: migraine with aura, subcortical ischemic events, mood disturbances, apathy, and cognitive impairment.
Notch3 is the only gene in which mutations are known to cause CADASIL. Most mutations in Notch3 in individuals with CADASIL are located in exon 4, followed by exons 3, 5, 6, and 11.

For more details, click here.

If you have any questions or comments, please do not hesitate to contact us

Best regards,

Doreen Niemann
Senior Director Strategic Communication
Centogene AG


Centogene AG
Schillingallee 68
18057 Rostock


Responsible: Doreen Niemann
USt-IdNr.: DE813228872